Patent on Biomarkers in Medical Research: A Focus on Neuropsychiatric Disorders
Suman Patel and Asim Ray
Affiliation: CSIR-National Institute of Science, Technology & Development Studies (NISTADS), Council of Scientific & Industrial Research (CSIR), Dr. K.S. Krishnan Marg, New Delhi 110 012, India.
Keywords: Biomarker, cerebrospinal fluid (CSF), epigenetics, miRNA, neuropsychiatric disorders, patent, plasma, serum.
Identification of putative biomarkers is a need of modern society today. Biomarker measures a biological or
pathogenic process that can predict disease prognosis. It is important for monitoring drug safety, identification of individuals
who are most likely to respond to specific treatments, stratification of presymptomatic patients and quantification
of treatment benefits. The peripheral blood based identification of biomarkers or disease signatures from psychiatric patients
possesses an immense potential towards drug developmental process. Biomarkers have been used as an early diagnostic
tool for neuropsychiatric disorders. Identification of potential biomarkers of psychiatric disorders has become most
important when it comes to biological psychiatry related research area. Patent provides a legal protection given to a new
invention which gives the holder exclusive right to use or sell the patented product. Hence, deep understanding towards
patent system is important as it protects novel research outputs that may lead to invention of new drugs. The present review
describes patents, its methods and validations focused on peripheral biomarkers including cerebrospinal fluid (CSF),
plasma, serum and various neuropsychiatric disorders.
Rights & PermissionsPrintExport